Novo Nordisk + OpenAI Deal
- Novo Nordisk announced a broad partnership with OpenAI covering drug discovery, manufacturing, supply chain, and workforce training. - Coverage describes the collaboration as embedding generative and agentic AI across the pharmaceutical value chain. - The pact is part of a wider trend where big pharma seeks to internalize AI capabilities across R&D and operations. (techround.co.uk)
Novo Nordisk said on April 14 that it is partnering with OpenAI to use artificial intelligence across how it discovers, makes, and delivers medicines. (novonordisk.com) The Danish drugmaker said the deal will apply OpenAI tools to drug discovery, manufacturing, supply chains, and employee training, not just one research team or one pilot program. (novonordisk.com) Novo Nordisk Chief Executive Mike Doustdar said the company wants to analyze larger datasets, spot patterns faster, and shorten the path from early research to patient use. OpenAI Chief Executive Sam Altman said life sciences is one of the industries where artificial intelligence can change day-to-day work. (cnbc.com) In pharmaceuticals, that means using software to sift through huge volumes of lab, clinical, and operations data the way a search engine scans the web. OpenAI says its life-sciences products are aimed at research and development, clinical work, regulatory tasks, and manufacturing. (openai.com) The scope matters because Novo Nordisk is treating artificial intelligence as core infrastructure, not as a side project for chemists. Reuters reported the company is deploying it across its business as it tries to move faster in obesity and diabetes medicines. (msn.com) That approach has been spreading through big drugmakers. OpenAI says Moderna has used ChatGPT Enterprise across legal, research, manufacturing, and commercial teams since 2023, giving Novo Nordisk a recent template for company-wide adoption. (openai.com) Novo Nordisk had already been building its own artificial-intelligence capacity before this deal. In June 2025, Nvidia said it was working with Novo Nordisk on custom models and agents tied to Denmark’s Gefion sovereign artificial-intelligence supercomputer for early research and clinical development. (nvidianews.nvidia.com) Investors treated the OpenAI announcement as a concrete business move, not a lab experiment. CNBC reported Novo Nordisk shares rose 2.8% shortly after the opening bell on April 14. (cnbc.com) The near-term test is whether Novo Nordisk can turn broad promises into faster experiments, cleaner factory planning, and more reliable medicine supply. The company framed the partnership around one metric that patients will notice first: getting new treatments to people sooner. (novonordisk.com)
